Inmar Inc. | July 11, 2017

Inmar Acquires MedEx Product Line from Aethon

Inmar today announced that it has acquired the MedEx product line from Aethon. The acquisition strengthens Inmar's technology- and analytics-based offerings for hospital pharmacies to increase compliance, efficiency and safety. Inmar also offers analytics, pharmaceutical product returns/recalls management and/or pharmacy financial management solutions in more than 5,000 hospitals across the U.S. and Canada.

The MedEx product line is a pharmacy logistics management solution geared specifically toward medications prepared and delivered from hospital pharmacies, addressing issues related to late, missing or divergent medication deliveries. The line includes three products: MedEx, TubeSafe and TraySafe, which consist of software and connected hardware that control, secure and track the preparation and distribution of medications.

"Advancements in medicine require that hospital pharmacies handle increasingly expensive, complex and highly regulated/controlled substances as they also work to protect patient safety and manage operational costs," says Inmar Chairman and CEO David Mounts. "Bringing together the MedEx line and Inmar's healthcare solutions and analytics capabilities present important opportunities to improve the safety and efficacy of the healthcare supply chain and enhance patient care.

"Inmar is an ideal company to acquire and grow the MedEx product line. They serve the hospital market and more specifically, they serve hospital pharmacies. With the addition of key MedEx employees from Aethon, their team is poised to take the product line to the next level. This sale to Inmar allows Aethon to focus exclusively on its core competencies related to autonomous mobile robot systems," says Aldo Zini, CEO of Aethon.

Inmar first entered the healthcare market in 2003 with its acquisition of Med-Turn, a provider of pharmaceutical reverse distribution management services and expanded its offerings for hospitals through its 2014 acquisition of EXP Pharmaceutical Solutions.

Financial terms were not disclosed.